Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells

Fig. 5

CMVSTs expressing iCHAR reduce responder alloreactive T-cells as assessed by secondary MLR. a Primary (1st) MLRs were labeled with CellTrace Violet 5 days after setup and then restimulated with PBMCs derived from the stimulator CMVST donor to generate secondary (2nd) MLRs. 2nd MLRs were analyzed by flow cytometry after 4–5 days. b Representative histogram plots showing CellTrace Violet staining on gated responder T-cells. Dilution of CellTrace Violet indicates cell proliferation. c Quantification of low CellTrace Violet stained responder T-cells to assess proliferation (mean ± SEM, n = 3). Significance was determined by paired two-tailed Student’s t-test. *p < 0.05 compared to iCHAR CMVST condition. R responder, S stimulator

Back to article page